Asieris Pharmaceuticals (688176.SH), a China-based global biopharma company specialising in discovering, developing and commercialising innovative drugs for the treatment of genitourinary tumours and other related diseases, announced on Tuesday that it has named Linda Wu, PhD as its new chief development officer, effective 17 January 2023.

Dr Wu will be a member of the company's executive leadership team, play a key role in the strategy development and management of the corporate's product portfolio, and the development and implementation of the global clinical range.

Dr Wu has more than 20 years of industry experiences and a successful track record in new drug R&D, commercialisation, and portfolio management, which includes extensive global experiences in building and heading clinical R&D teams to successfully introduce innovative oncology products in China and global markets. She has served as a group medical director of Oncology, US Medical Affairs at Janssen Pharmaceuticals and senior director and the head of Clinical Development of Oncology, and the Compound Development team leader at Janssen in China. She has more than ten years of research and management experiences in drug discovery at Bayer Pharmaceuticals and Janssen.